Clinical Trials Logo
  1. Home
  2. Semantic Dementia
  3. NCT05184569

Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology — Veri-T-001  

Semantic Dementia Clinical Trial

Official title:
Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Oral Verdiperstat (BHV-3241) in Patients With Semantic Variant Primary Progressive Aphasia (svPPA) Due to TDP-43 Pathology

Clinical Trial Summary

The purpose of the study is to test the safety and tolerability of twice daily Verdiperstat in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). Three-fourths of the participants will receive Verdiperstat and one-fourth will receive Placebo during the 24-week treatment duration.

Clinical Trial Description

This is a Phase 1, randomized, double-blind, placebo-controlled study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Verdiperstat in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). Approximately 64 subjects will be randomized 3:1 to active drug or placebo. Study drug will be administered orally bid (two Verdiperstat tablets bid or two placebo tablets bid (for a total daily dose of 600mg daily, following a one-week titration period of 1 tablet daily). The study will test the effects of Verdiperstat on cerebrospinal fluid (CSF) proteins, brain magnetic resonance imaging (MRI), and cognitive (thinking, memory and language) tests in subjects with svPPA due to FTLD-TDP. This study uses placebo which looks like the experimental drug but does not have any active drug in it. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05184569
Study type Interventional
Source University of California, San Francisco
Contact Karin Snowberg, BA, MA
Phone 415-476-8845
Email Karin.Snowberg@ucsf.edu
Status Recruiting
Phase Phase 1
Start date April 19, 2022
Completion date September 30, 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT00545974 - Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Phase 4
Completed NCT04597827 - Metacognition in Semantic Dementia: Comparison With Alzheimer's Disease
Enrolling by invitation NCT04680130 - Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders
Recruiting NCT03481933 - Evaluation of a Transcranial Stimulation With Direct Current on Language Disorders in Semantic Dementia N/A
Recruiting NCT03174938 - The Swedish BioFINDER 2 Study N/A
Completed NCT01623284 - PiB PET Scanning in Speech and Language Based Dementias Phase 1
Recruiting NCT05800028 - Memory and Social Interactions
Active, not recruiting NCT04881617 - Treatment for Speech and Language in Primary Progressive Aphasia N/A
Completed NCT02819700 - Evaluation and Characterization of Behavioural Disorders and Dementias by the Behavioural Dysexecutive Syndrome Inventory (BDSI)
Not yet recruiting NCT06218732 - Revealing Engagement Dynamics Among Semantic Dementia Patients
Recruiting NCT02964637 - Diagnosing Frontotemporal Lobar Degeneration
Completed NCT00957710 - Language Treatment for Progressive Aphasia N/A
Active, not recruiting NCT06181500 - Home-Based Exercise in Primary Progressive Aphasia (HEPPA) N/A